Data / Research funding / California / Trethera Corporation
Trethera Corporation: 10 NIH awards ($10.8M), fiscal years 2021 to 2026
Trethera Corporation in Sherman Oaks, CA is funded under 10 NIH awards ($10.8M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- QB66ZMAUF5P7
- State
- California
Awards
10 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,050,000 | July 2, 2024 | June 30, 2026 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types | NIH | National Cancer Institute | 2023 to 2024 | $2,046,375 | June 1, 2023 | May 31, 2025 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | NIH | National Eye Institute | 2022 to 2025 | $1,606,501 | September 30, 2022 | January 31, 2026 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors | NIH | National Cancer Institute | 2025 | $1,150,000 | August 18, 2025 | July 31, 2027 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $994,978 | August 7, 2025 | July 31, 2028 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $905,290 | September 18, 2023 | August 31, 2027 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $610,850 | June 21, 2023 | May 31, 2025 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $601,607 | August 1, 2023 | July 31, 2025 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer | NIH | National Cancer Institute | 2025 | $406,500 | September 8, 2025 | August 31, 2026 | SCHULTZ, KENNETH | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 | $395,119 | September 18, 2023 | November 30, 2024 | SCHULTZ, KENNETH | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 6 | $5,079,216 | 0 | $0 |
| 2024 | 5 | $2,965,289 | 0 | $0 |
| 2023 | 4 | $2,354,520 | 0 | $0 |
| 2022 | 1 | $368,195 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 4 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 4 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 4 awards here |
Topics of its NIH awards
- Autoimmune Disease
- Translational Research
- Brain Disorders
- Multiple Sclerosis
- Neurodegenerative
- Neurosciences
- Cancer
- Biotechnology
- Precision Medicine
- Orphan Drug
- Pediatric
- Rare Diseases
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.